McKesson (NYSE:MCK) Price Target Lowered to $1,015.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan lowered its price target on McKesson to $1,015 from $1,107, while keeping an overweight rating. The new target still implies about 37.8% upside from the current share price.
• McKesson’s stock was down 2.4% to $736.54 on Friday, even after the company posted quarterly EPS of $11.69, which beat estimates. However, revenue of $96.3 billion came in below expectations, helping pressure the shares.
• Analyst sentiment remains broadly positive: 14 analysts rate the stock a Buy and only 3 Hold, with an average price target of $970.73. The article also notes recent insider selling and heavy institutional ownership of 85.07%.

McKesson (NYSE:MCK - Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $1,107.00 to $1,015.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target would indicate a potential upside of 37.81% from the stock's current price.

MCK has been the subject of several other research reports. Wells Fargo & Company lifted their price target on McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 5th. Bank of America dropped their price target on McKesson from $1,040.00 to $1,000.00 and set a "buy" rating for the company in a research note on Monday, April 6th. Wall Street Zen raised McKesson from a "hold" rating to a "buy" rating in a research note on Saturday, May 2nd. Evercore reaffirmed an "outperform" rating on shares of McKesson in a research note on Thursday, March 5th. Finally, TD Cowen lifted their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a "buy" rating in a research note on Thursday, February 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $970.73.

McKesson Stock Down 2.4%

NYSE:MCK traded down $18.22 during trading hours on Friday, hitting $736.54. 1,448,859 shares of the company's stock traded hands, compared to its average volume of 809,905. The firm has a market cap of $90.22 billion, a P/E ratio of 21.19, a P/E/G ratio of 1.07 and a beta of 0.35. McKesson has a 52 week low of $637.00 and a 52 week high of $999.00. The business's fifty day simple moving average is $883.74 and its two-hundred day simple moving average is $859.93.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same quarter last year, the company earned $10.12 earnings per share. The firm's quarterly revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, analysts expect that McKesson will post 39.02 EPS for the current year.

Insider Activity

In other news, EVP Michele Lau sold 2,725 shares of the business's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company's stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Maria Martinez sold 349 shares of the business's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the sale, the director directly owned 301 shares of the company's stock, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 3,264 shares of company stock valued at $3,205,315. Insiders own 0.08% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MCK. Norges Bank purchased a new position in McKesson during the 4th quarter valued at about $1,651,137,000. Swedbank AB increased its holdings in McKesson by 42.2% during the 4th quarter. Swedbank AB now owns 886,283 shares of the company's stock valued at $727,009,000 after purchasing an additional 263,189 shares during the period. SurgoCap Partners LP increased its holdings in McKesson by 68.7% during the 3rd quarter. SurgoCap Partners LP now owns 452,261 shares of the company's stock valued at $349,390,000 after purchasing an additional 184,106 shares during the period. Robeco Institutional Asset Management B.V. increased its holdings in McKesson by 73.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 432,578 shares of the company's stock valued at $354,839,000 after purchasing an additional 183,590 shares during the period. Finally, Danica Pension Livsforsikringsaktieselskab purchased a new position in McKesson during the 3rd quarter valued at about $135,352,000. Hedge funds and other institutional investors own 85.07% of the company's stock.

McKesson News Roundup

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q4 EPS beat and margin improvement: McKesson reported non-GAAP EPS of $11.69 (vs. $11.56 est.) and said oncology and specialty distribution helped lift segment margins — evidence of higher-margin growth areas underpinning profitability. MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
• Positive Sentiment: Stronger liquidity: McKesson secured a new $5.0 billion multi-currency revolving credit facility, extending committed liquidity and giving management more flexibility for capital allocation and operations. Does McKesson's (MCK) Bigger Credit Line Quietly Redefine Its Capital Allocation Priorities?
• Positive Sentiment: Analyst support: William Blair reiterated a Buy rating, citing durable earnings power and fiscal 2027 growth prospects despite near-term revenue softness. That provides third‑party validation of the company’s longer-term thesis. McKesson: Durable Earnings Power and Fiscal 2027 Growth Outlook Underpin Buy Rating Despite Near-Term Revenue Softness
• Neutral Sentiment: Company disclosures: McKesson posted its full Q4 and FY2026 results, an investor presentation and the earnings webcast — useful for modeling but not market-moving on their own. McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
• Neutral Sentiment: Earnings call transcript available for details on segment trends and management commentary. McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Revenue shortfall: Quarterly revenue of $96.30B missed consensus (~$101.35B), which likely triggered the sell‑the‑news reaction despite the EPS beat; investors often punish topline misses in a distribution business. McKesson NYSE: MCK Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Guidance and expectations: FY2027 EPS guidance (43.80–44.60) is close to consensus but not a clear beat, leaving room for disappointment; that, plus the revenue miss, outweighed positives for traders today. McKesson Q4 earnings & guidance (MarketBeat summary)

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.